Transplantation for Patients With Chronic Lymphocytic Leukemia

Overview

To evaluate the role of high dose therapy and autologous or allogeneic hematopoietic cell transplantation for the treatment of chronic lymphocytic leukemia.

Full Title of Study: “Autologous and Allogeneic Peripheral Blood Progenitor (PBPC) Transplantation for Patients With Chronic Lymphocytic Leukemia”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 2010

Detailed Description

To determine effectiveness of allogeneic transplantation in eradicating chronic lymphocytic leukemia.

Interventions

  • Procedure: high dose chemotherapy then autologous hematopoietic cell transplant
  • Procedure: ablative allogeneic hematopoietic cell transplant

Clinical Trial Outcome Measures

Primary Measures

  • Efficacy

Secondary Measures

  • Feasibility
  • Toxicity
  • olymerase Chain Reaction (PCR) for minimal residual disease

Participating in This Clinical Trial

Inclusion Criteria

  • adequate organ function – normal bone marrow cytogenetics Exclusion Criteria:
  • active CNS disease – For autologous patients more than 30% bone marrow involvement

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Stanford University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Robert Negrin, Professor – Stanford University
  • Overall Official(s)
    • Robert S Negrin, Principal Investigator, Stanford University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.